A Review Article on Different Types of Medications Used in Diabetes Mellitus
Corresponding Author(s) : G.Kiran
kirn1987@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 10 No. 4 (2022): 2022 Volume -10 - Issue 4
Abstract
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients.
Keywords
Type 2 diabetes mellitus, Treatment, Oral antidiabetic agents, Injectable antidiabetic agents, Older people, Renal impairment, Future treatments etc.
1.
G.Kiran, I.Divya, Ch.Abidha, K.Praveen, P.Abhinandhana. A Review Article on Different Types of Medications Used in Diabetes Mellitus. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2023 Jan. 6 [cited 2026 Apr. 19];10(4):489-93. Available from: https://ijamscr.com/ijamscr/article/view/1275
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-101. doi: 10.1056/NEJMoa0908292, PMID pubMed, Google Scholar.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood – glucose control with Sulphonylireas or insulin compared with Conventional treatment and risk of Complications in patients with type ?2 Diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. PMID 9742976.
3. Holman RR, Paul SK, Bethel MA. Matthew’s DT, Neil HA. 10 year follow up of intensive glucose control in type ?2 Dibates. N Engl J Med. 2008;359:1577-89.
4. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type ?2 Diabetes. N Engl J Med. 2003;348(5):383-93. doi: 10.1056/NEJMoa021778.
5. Suzanne Falco MD. By Pippa Wysong on March. 21; 2019.
6. Kelly wood, MD – by Rachel Nall MSN, CRNA-updated on November 29, 2021.
7. Carter A. By Kristen Cherney – updated on October 12, 2022.
8. Gamelan K, Rana MBM, Sultan S. Oral hypoglycemic Medicatios. [updated on May 8 2022]. In: Stampers (internet). Treasure Island, (FL): Stampers Publishing; 2022 January-.
9. Shivaprasad C, Sanjay Kalra. Bromocriptine in type 2 diabetes mellitus. July 2011; 15( Suppl1) - p S17-S24 doi: 10.4103/2230-8210.83058
10. Patel A, Mac Mahon S, Chalmers J, et al. Advance Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type ?2 Diabetes. N Engl J Med. 2008;358(24):2560-72. doi: 10.1056/NEJMoa0802987, PMID pubMed.
References
1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-101. doi: 10.1056/NEJMoa0908292, PMID pubMed, Google Scholar.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood – glucose control with Sulphonylireas or insulin compared with Conventional treatment and risk of Complications in patients with type ?2 Diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. PMID 9742976.
3. Holman RR, Paul SK, Bethel MA. Matthew’s DT, Neil HA. 10 year follow up of intensive glucose control in type ?2 Dibates. N Engl J Med. 2008;359:1577-89.
4. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type ?2 Diabetes. N Engl J Med. 2003;348(5):383-93. doi: 10.1056/NEJMoa021778.
5. Suzanne Falco MD. By Pippa Wysong on March. 21; 2019.
6. Kelly wood, MD – by Rachel Nall MSN, CRNA-updated on November 29, 2021.
7. Carter A. By Kristen Cherney – updated on October 12, 2022.
8. Gamelan K, Rana MBM, Sultan S. Oral hypoglycemic Medicatios. [updated on May 8 2022]. In: Stampers (internet). Treasure Island, (FL): Stampers Publishing; 2022 January-.
9. Shivaprasad C, Sanjay Kalra. Bromocriptine in type 2 diabetes mellitus. July 2011; 15( Suppl1) - p S17-S24 doi: 10.4103/2230-8210.83058
10. Patel A, Mac Mahon S, Chalmers J, et al. Advance Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type ?2 Diabetes. N Engl J Med. 2008;358(24):2560-72. doi: 10.1056/NEJMoa0802987, PMID pubMed.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood – glucose control with Sulphonylireas or insulin compared with Conventional treatment and risk of Complications in patients with type ?2 Diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. PMID 9742976.
3. Holman RR, Paul SK, Bethel MA. Matthew’s DT, Neil HA. 10 year follow up of intensive glucose control in type ?2 Dibates. N Engl J Med. 2008;359:1577-89.
4. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type ?2 Diabetes. N Engl J Med. 2003;348(5):383-93. doi: 10.1056/NEJMoa021778.
5. Suzanne Falco MD. By Pippa Wysong on March. 21; 2019.
6. Kelly wood, MD – by Rachel Nall MSN, CRNA-updated on November 29, 2021.
7. Carter A. By Kristen Cherney – updated on October 12, 2022.
8. Gamelan K, Rana MBM, Sultan S. Oral hypoglycemic Medicatios. [updated on May 8 2022]. In: Stampers (internet). Treasure Island, (FL): Stampers Publishing; 2022 January-.
9. Shivaprasad C, Sanjay Kalra. Bromocriptine in type 2 diabetes mellitus. July 2011; 15( Suppl1) - p S17-S24 doi: 10.4103/2230-8210.83058
10. Patel A, Mac Mahon S, Chalmers J, et al. Advance Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type ?2 Diabetes. N Engl J Med. 2008;358(24):2560-72. doi: 10.1056/NEJMoa0802987, PMID pubMed.